Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Clinical Measurement
100%
Antiplatelet Drugs
100%
Antiplatelet Drug Resistance
100%
Unresponsiveness
50%
Clinical Trials
33%
Adverse Clinical Outcomes
33%
Pharmacokinetics
16%
Patients with Cardiovascular Diseases
16%
Drug Interactions
16%
Cytochrome P450 Activity
16%
Well-defined
16%
Clinical Benefit
16%
Therapeutic Strategies
16%
Platelet Response
16%
Randomized Clinical Trial
16%
Antiplatelet Agents
16%
Drug Bioavailability
16%
Drug Therapy
16%
Inter-individual Variation
16%
Drug Dosing
16%
Increased Dose
16%
Laboratory Assessment
16%
Genetic Polymorphism
16%
Antiplatelet Activity
16%
Strategies to Overcome
16%
Patients with Coronary Artery Disease
16%
Adverse Cardiovascular Events
16%
Platelet Function
16%
Laboratory Methods
16%
Dual Antiplatelet Therapy
16%
Dosing Regimen
16%
Clinical Events
16%
Medication Nonadherence
16%
Adverse Outcomes
16%
Pharmacology, Toxicology and Pharmaceutical Science
Antithrombocytic Agent
100%
Drug Resistance
100%
Antiplatelet
42%
Clinical Trial
28%
Pharmacokinetics
14%
Coronary Artery Disease
14%
Randomized Clinical Trial
14%
Adverse Outcome
14%
Pharmacotherapy
14%
Cytochrome P450
14%
Bioavailability
14%
Cardiovascular Disease
14%
Observational Study
14%
Drug-Drug Interaction
14%